Windlas Biotech Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Windlas Biotech Ltd filed with BSE on 14 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Windlas Biotech reported its highest ever quarterly revenue of Rs 248 crore in Q1 FY27, up 18% year-on-year, marking 14 consecutive quarters of record revenue. The Generic Formulations CDMO vertical grew 29% year-on-year while Trade Generics & Institutional revenue declined following discontinuation of codeine-based products, and Exports grew 79% year-on-year. Management said Plant 6 remains on track for commercialization in H1 FY27 and discussed capacity, working capital and API price volatility during the quarter.
Numbers mentioned
Revenue: INR248 crores (Q1 FY27)
p. 3
“delivering its highest ever quarterly revenue of INR248 crores, representing 18% Y-o-Y growth”
Hitesh Windlass, page 3 of the filed PDF · View the filing
EBITDA (ex-ESOP expense): INR34 crores, up 26% Y-o-Y (Q1 FY27)
p. 4
“Excluding the impact of ESOP expenses, which are non-cash in nature, INR7.2 crores, our EBITDA grew 26% Y-o-Y to INR34 crores”
Komal Gupta, page 4 of the filed PDF · View the filing
PBT and PAT (ex-ESOP expense): INR30 crores and INR25 crores, up 27% and 37% Y-o-Y (Q1 FY27)
p. 4
“PBT and PAT grew 27% and 37% Y-o-Y to INR30 crores and INR25 crores, respectively, reflecting our continued focus on improving operational leverage”
Komal Gupta, page 4 of the filed PDF · View the filing
EBITDA, PBT, PAT (including ESOP expense): EBITDA INR27 crores, PBT INR23 crores, PAT INR18 crores (Q1 FY27)
p. 4
“the company reported EBITDA INR27 crores, PBT INR23 crores and PAT INR18 crores”
Komal Gupta, page 4 of the filed PDF · View the filing
Earnings per share: INR8.46 (Q1 FY27)
p. 4
“For Q1 FY27, earnings per share has improved to INR8.46”
Komal Gupta, page 4 of the filed PDF · View the filing
Generic Formulations CDMO revenue: INR207 crores, up 29% Y-o-Y (Q1 FY27)
p. 4
“Our Generic Formulations CDMO vertical delivered 29% Y-o-Y revenue growth to INR207 crores, driven by customer expansion, deeper customer engagement and new product launches”
Komal Gupta, page 4 of the filed PDF · View the filing
Trade Generics & Institutional revenue: INR30 crores (Q1 FY27)
p. 4
“The Trade Generics & Institutional vertical reported revenue of INR30 crores, following discontinuation of codeine-based products”
Komal Gupta, page 4 of the filed PDF · View the filing
Exports revenue: INR11 crores, up 79% Y-o-Y (Q1 FY27)
p. 4
“Our Exports vertical recorded 79% Y-o-Y growth to INR11 crores”
Komal Gupta, page 4 of the filed PDF · View the filing
Buyback amount: INR47 crores (Q1 FY27)
p. 4
“the company also completed INR47 crores buyback in which promoters did not participate”
Komal Gupta, page 4 of the filed PDF · View the filing
FY26 dividend: INR13 crores, INR6.30 per equity share (FY26)
p. 4
“declaration of FY26 dividend of INR13 crores, INR6.30 per equity share”
Komal Gupta, page 4 of the filed PDF · View the filing
Indian Pharma Market volume growth: 3.4% (Q1 FY27)
p. 3
“The Indian pharma market witnessed a volume growth of 3.4% in Q1 of FY27, reflecting a steady yet measured industry environment”
Hitesh Windlass, page 3 of the filed PDF · View the filing
Maintenance capex: INR12 crores to INR15 crores every year
p. 8
“Some of it also goes into the maintenance capex every year that gets done INR12 crores to INR15 crores every year”
Komal Gupta, page 8 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Plant 6 commercialization — H1 FY27 / end of H1 · H1 FY27
stated firmly by Hitesh Windlass
p. 3
“We are on track for the commercialization of Plant 6 in H1 of FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities”
Hitesh Windlass, page 3 of the filed PDF · View the filing
Plant 6 timing — end of Q2 / end of H1 · end of H1 FY27
stated firmly by Hitesh Windlass
p. 17
“So, we have said Plant 6 will be coming in at the end of Q2. The H1, end of H1. So yes, maybe 15 days plus/minus could be there, but that's what we are targeting.”
Hitesh Windlass, page 17 of the filed PDF · View the filing
Revenue capacity with Plant 6 — INR1,100 crores
stated as an aspiration by Komal Gupta
p. 8
“we have mentioned earlier that with Plant 6 we can deliver INR1,100 crores kind of a number in terms of revenue”
Komal Gupta, page 8 of the filed PDF · View the filing
Further revenue potential beyond Plant 6 estimate — 10% to 15% more
stated as an aspiration by Komal Gupta
p. 8
“we have always in past seen that the initial estimate that we give in terms of revenue that can be delivered with our plants can be grown to a large extent, 10% to 15% more with various efficiency initiatives that we consistently take internally”
Komal Gupta, page 8 of the filed PDF · View the filing
Additional revenue potential with Plant 6 — INR100 crore to INR150 crores further increase
stated as an aspiration by Komal Gupta
p. 13
“there is -- we see clearly INR100 crore, INR150 crores kind of further increase with Plant 6 possibility against the number that we already mentioned”
Komal Gupta, page 13 of the filed PDF · View the filing
Quarterly depreciation run rate post Plant 6 — around 30 million per quarter · initial 1 year post commissioning
stated conditionally by Komal Gupta
p. 9
“but around 30 million per quarter should be the number initially, initial 1 year and then it goes down as you have seen the quarter depreciation reduction”
Komal Gupta, page 9 of the filed PDF · View the filing
Extra depreciation from Plant 6 — Q2 and Q3
stated firmly by Komal Gupta
p. 17
“Yes, something in Q2 and Q3 it will be full.”
Komal Gupta, page 17 of the filed PDF · View the filing
New capex/capacity decision
stated conditionally by Komal Gupta
p. 13
“any point of time where we see that we need extra capacities also to come in place, then we would start working on another organic growth”
Komal Gupta, page 13 of the filed PDF · View the filing
Injectables capacity expansion timeline — 6 to 8 months
stated conditionally by Hitesh Windlass
p. 11
“when we take a decision to enhance capacity, it will be around 6 to 8 months kind of a process to add the machinery, qualify it and bring it online”
Hitesh Windlass, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said quarterly growth figures should be treated cautiously and that no long-term factors in any vertical have changed.
Answered by Komal Gupta
Asked by Dhwanil Desai: What is driving the 29% CDMO growth and is it sustainable given injectables' contribution?
p. 5
“it is important to look at our growth, which is consistently maintained at a company level instead of going vertical-wise”
Komal Gupta, page 5 of the filed PDF · View the filing
Management declined to give growth guidance and said sustained execution across product range, geography and go-to-market strategy is the path to bridging the gap.
Answered by Hitesh Windlass
Asked by Dhwanil Desai: Even excluding codeine revenue, Trade Generics appears stagnant for several quarters - how should this be read and will growth return?
p. 5
“So, Dhwanil, first is that, as you know, we do not give guidance. So, I would not comment on what could be the growth going forward.”
Hitesh Windlass, page 5 of the filed PDF · View the filing
Management said the signal of success will be revenue and cash flow generation, with plant-level customer approvals and new customer additions as intermediate steps.
Answered by Hitesh Windlass
Asked by Sajal Kapoor: What operating milestones should shareholders track as Plant 6 capacity comes online?
p. 6
“the signal of our success will still come in revenue, will still come in our cash flow generation, as you mentioned”
Hitesh Windlass, page 6 of the filed PDF · View the filing
Management said they focus on execution rather than trying to predict whether the IPM growth trend will persist.
Answered by Hitesh Windlass
Asked by Kumar Saurabh: What is management's reading of the recent uptick in IPM growth and is it sustainable?
p. 7
“I don't want to say that the tide has turned and pretend to know more than what anybody in the industry can say”
Hitesh Windlass, page 7 of the filed PDF · View the filing
Management said peak utilization is typically 60-65%, stretchable to about 70%, and that the INR1,100 crore revenue target from Plant 6 has room to grow further.
Answered by Komal Gupta
Asked by Kumar Saurabh: What is peak capacity utilization achievable and will export growth continue?
p. 8
“we have said that 60% to 65% is the highest peak utilization level for our kind of business, which can, of course, be stretched to 70% or so”
Komal Gupta, page 8 of the filed PDF · View the filing
Management acknowledged the codeine loss has impacted momentum in TGx and Institutional vertical, calling it a temporary hit.
Answered by Komal Gupta
Asked by Avnish Burman: Has ex-codeine Trade Generics business grown year-on-year this quarter?
p. 8
“with codeine being taken away, there has been some impact to our TGx and institutional vertical in terms of the momentum that we have been maintaining”
Komal Gupta, page 8 of the filed PDF · View the filing
Management cited increments, higher contractual manpower tied to production, and a retrospective minimum wage increase by the Uttarakhand government.
Answered by Komal Gupta
Asked by Avnish Burman: Why did employee costs (ex-ESOP) grow 17% Y-o-Y?
p. 9
“there has been further increase in the minimum wage by Uttarakhand government. So that increase has also become part of it”
Komal Gupta, page 9 of the filed PDF · View the filing
Management said inventory and receivable days increased temporarily during the quarter due to geopolitical factors but were brought back to similar levels by quarter end.
Answered by Komal Gupta
Asked by Avnish Burman: Did working capital increase this quarter due to geopolitical/crude price factors?
p. 9
“there have been some factors in terms of increase in -- because of geopolitical factors, some increase in inventory was there. And accordingly, some increase in receivable days was also there”
Komal Gupta, page 9 of the filed PDF · View the filing
Management confirmed injectables is on track based on customer feedback and inquiries.
Answered by Hitesh Windlass
Asked by Ishit Desai: Is the injectables business now back on track after a slower ramp-up?
p. 11
“Yes, that is correct.”
Hitesh Windlass, page 11 of the filed PDF · View the filing
Management said it is hard to isolate the API price impact given the transparent, cost-plus nature of pricing with customers, and confirmed growth was mostly volume-linked.
Answered by Hitesh Windlass
Asked by Vansh Gupta: Have API price changes had a positive impact on this quarter's top line given competitors reported higher realizations?
p. 12
“Our focus has been to increase our ability to supply and increase our output as opposed to looking at shaving or getting some temporary advantage in margin.”
Hitesh Windlass, page 12 of the filed PDF · View the filing
Management said some Plant 6-designated machines were already used in existing Plant 2 extension this quarter, and further capacity would come through debottlenecking before any new capex project.
Answered by Komal Gupta
Asked by Resham Jain: With revenue run-rate nearing the Plant 6 capacity ceiling, how is further capacity addition being planned?
p. 13
“we would first instead of starting a new capex project, we would first want to completely focus in terms of increasing, enhancing this capacity in terms of revenue that can be delivered from existing plants”
Komal Gupta, page 13 of the filed PDF · View the filing
Management said they prefer incremental capacity expansion over large plants to maintain control over working capital, cash flows and margins.
Answered by Komal Gupta
Asked by Dhwanil Desai: Is management considering consolidating manufacturing into larger blocks for efficiency instead of phased expansion?
p. 15
“We don't think that having a huge plant facility would really do benefit us. We believe in having incremental capacity expansion”
Komal Gupta, page 15 of the filed PDF · View the filing
Management attributed margin performance to business mix, operational efficiencies and increased contribution from value-added CDMO products.
Answered by Komal Gupta
Asked by Avnish Tiwari: What drove the strong gross margin performance this quarter despite lower Trade Generics mix?
p. 15
“the gross margin that we have been able to deliver, they are mainly driven by business mix, operational efficiencies that we have been able to bring in, and the product portfolio within -- especially within CDMO vertical that we were able to convert in this quarter”
Komal Gupta, page 15 of the filed PDF · View the filing
Management said volatility persists and stabilization has not yet occurred.
Answered by Hitesh Windlass
Asked by Avnish Tiwari: Are API prices stabilizing or still volatile?
p. 16
“the impression that I have in my mind is of volatility only. The stability is still to be there.”
Hitesh Windlass, page 16 of the filed PDF · View the filing
Risks flagged
Loss of codeine-based cough syrup products impacting Trade Generics & Institutional revenue
p. 4
“The Trade Generics & Institutional vertical reported revenue of INR30 crores, following discontinuation of codeine-based products”
Komal Gupta, page 4 of the filed PDF · View the filing
Volatility in API prices and material availability linked to geopolitical crisis in West Asia
p. 11
“The prices have been varying quite a bit with the crude situation.”
Hitesh Windlass, page 11 of the filed PDF · View the filing
Increase in minimum wage mandated by Uttarakhand government raising personnel costs
p. 9
“there has been further increase in the minimum wage by Uttarakhand government. So that increase has also become part of it”
Komal Gupta, page 9 of the filed PDF · View the filing
Institutional revenue lumpiness making year-on-year comparisons difficult
p. 8
“institutional revenue, as we have earlier also mentioned is very lumpy in nature”
Komal Gupta, page 8 of the filed PDF · View the filing
Ongoing API price volatility with stabilization not yet visible
p. 16
“I don't see that stabilization -- I would be very incorrect to say that stabilization is already appear.”
Hitesh Windlass, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.